nach oben

NeuroMolecular Medicine

Erschienen in:

02.01.2019 | Review Paper

The Emerging Roles of Ferroptosis in Huntington’s Disease

verfasst von: Yajing Mi, Xingchun Gao, Hao Xu, Yuanyuan Cui, Yuelin Zhang, Xingchun Gou

Erschienen in: NeuroMolecular Medicine | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Huntington’s disease (HD) is an autosomal dominant and fatal neurodegenerative disorder, which is caused by an abnormal CAG repeat in the huntingtin gene. Despite its well-defined genetic origin, the molecular mechanisms of neuronal death are unclear yet, thus there are no effective strategies to block or postpone the process of HD. Ferroptosis, a recently identified iron-dependent cell death, attracts considerable attention due to its putative involvement in neurodegenerative diseases. Accumulative data suggest that ferroptosis is very likely to participate in HD, and inhibition of the molecules and signaling pathways involved in ferroptosis can significantly eliminate the symptoms and pathology of HD. This review first describes evidence for the close relevance of ferroptosis and HD in patients and mouse models, then summarizes advances for the mechanisms of ferroptosis involved in HD, finally outlines some therapeutic strategies targeted ferroptosis. Comprehensive understanding of the emerging roles of ferroptosis in the occurrence of HD will help us to explore effective therapies for slowing the progression of this disease.

Abdalkader, M., Lampinen, R., Kanninen, K. M., Malm, T. M., & Liddell, J. R. (2018). Targeting Nrf2 to suppress ferroptosis and mitochondrial dysfunction in neurodegeneration. Frontiers in Neuroscience, 12, 466. https://doi.org/10.3389/fnins.2018.00466.CrossRefPubMedPubMedCentral

Angeli, J. P. F., Shah, R., Pratt, D. A., & Conrad, M. (2017). Ferroptosis inhibition: Mechanisms and opportunities. Trends in Pharmacological Sciences, 38(5), 489–498. https://doi.org/10.1016/j.tips.2017.02.005.CrossRefPubMed

Ayala-Pena, S. (2013). Role of oxidative DNA damage in mitochondrial dysfunction and Huntington’s disease pathogenesis. Free Radical Biology and Medicine, 62, 102–110. https://doi.org/10.1016/j.freeradbiomed.2013.04.017.CrossRefPubMed

Baird, L., & Dinkova-Kostova, A. T. (2011). The cytoprotective role of the Keap1-Nrf2 pathway. Archives of Toxicology, 85(4), 241–272. https://doi.org/10.1007/s00204-011-0674-5.CrossRefPubMed

Barbiroli, B., Frassineti, C., Martinelli, P., Iotti, S., Lodi, R., Cortelli, P., & Montagna, P. (1997). Coenzyme Q10 improves mitochondrial respiration in patients with mitochondrial cytopathies. An in vivo study on brain and skeletal muscle by phosphorous magnetic resonance spectroscopy. Cellular and Molecular Biology (Noisy-le-grand), 43(5), 741–749.

Bartzokis, G., Lu, P. H., Tishler, T. A., Fong, S. M., Oluwadara, B., Finn, J. P.,… Perlman, S. (2007). Myelin breakdown and iron changes in Huntington’s disease: Pathogenesis and treatment implications. Neurochemical Research, 32(10), 1655–1664. https://doi.org/10.1007/s11064-007-9352-7.CrossRefPubMed

Bradford, J., Shin, J. Y., Roberts, M., Wang, C. E., Sheng, G., Li, S., & Li, X. J. (2010). Mutant huntingtin in glial cells exacerbates neurological symptoms of Huntington disease mice. Journal of Biological Chemistry, 285(14), 10653–10661. https://doi.org/10.1074/jbc.M109.083287.CrossRefPubMed

Browne, S. E., & Beal, M. F. (2006). Oxidative damage in Huntington’s disease pathogenesis. Antioxidants & Redox Signaling, 8(11–12), 2061–2073. https://doi.org/10.1089/ars.2006.8.2061.CrossRef

Cao, J. Y., & Dixon, S. J. (2016). Mechanisms of ferroptosis. Cellular and Molecular Life Sciences, 73(11–12), 2195–2209. https://doi.org/10.1007/s00018-016-2194-1.CrossRefPubMedPubMedCentral

Cardoso, B. R., Hare, D. J., Bush, A. I., & Roberts, B. R. (2017). Glutathione peroxidase 4: A new player in neurodegeneration? Molecular Psychiatry, 22(3), 328–335. https://doi.org/10.1038/mp.2016.196.CrossRefPubMed

Cheah, J. H., Kim, S. F., Hester, L. D., Clancy, K. W., Patterson, S. E. 3rd, Papadopoulos, V., & Snyder, S. H. (2006). NMDA receptor-nitric oxide transmission mediates neuronal iron homeostasis via the GTPase Dexras1. Neuron, 51(4), 431–440. https://doi.org/10.1016/j.neuron.2006.07.011.CrossRefPubMedPubMedCentral

Chen, J., Marks, E., Lai, B., Zhang, Z., Duce, J. A., Lam, L. Q., Volitakis, I., Bush, A. I., Hersch, S., & Fox, J. H. (2013). Iron accumulates in Huntington’s disease neurons: Protection by deferoxamine. PLoS ONE, 8(10), e77023. https://doi.org/10.1371/journal.pone.0077023.CrossRefPubMedPubMedCentral

Chen, L., Hambright, W. S., Na, R., & Ran, Q. (2015). Ablation of the ferroptosis inhibitor glutathione peroxidase 4 in neurons results in rapid motor neuron degeneration and paralysis. Journal of Biological Chemistry, 290(47), 28097–28106. https://doi.org/10.1074/jbc.M115.680090.CrossRefPubMed

Cheng, S. Y., Wang, S. C., Lei, M., Wang, Z., & Xiong, K. (2018). Regulatory role of calpain in neuronal death. Neural Regeneration Research, 13(3), 556–562. https://doi.org/10.4103/1673-5374.228762.CrossRefPubMedPubMedCentral

Choi, B. R., Bang, S., Chen, Y., Cheah, J. H., & Kim, S. F. (2013). PKA modulates iron trafficking in the striatum via small GTPase. Rhes. Neuroscience, 253, 214–220. https://doi.org/10.1016/j.neuroscience.2013.08.043.CrossRefPubMed

Choo, Y. S., Johnson, G. V., MacDonald, M., Detloff, P. J., & Lesort, M. (2004). Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Human Molecular Genetics, 13(14), 1407–1420.CrossRef

Conrad, M., Kagan, V. E., Bayir, H., Pagnussat, G. C., Head, B., Traber, M. G., & Stockwell, B. R. (2018). Regulation of lipid peroxidation and ferroptosis in diverse species. Genes & Development, 32(9–10), 602–619. https://doi.org/10.1101/gad.314674.118.CrossRef

Crotti, A., Benner, C., Kerman, B. E., Gosselin, D., Lagier-Tourenne, C., Zuccato, C., Cattaneo, E., Gage, F. H., Cleveland, D. W., & Glass, C. K. (2014). Mutant Huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors. Nature Neuroscience, 17(4), 513–521. https://doi.org/10.1038/nn.3668.CrossRefPubMedPubMedCentral

Cui, L., Jeong, H., Borovecki, F., Parkhurst, C. N., Tanese, N., & Krainc, D. (2006). Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell, 127(1), 59–69. https://doi.org/10.1016/j.cell.2006.09.015.CrossRefPubMed

Deas, E., Cremades, N., Angelova, P. R., Ludtmann, M. H., Yao, Z., Chen, S.,… Abramov, A. Y. (2016). Alpha-synuclein oligomers interact with metal ions to induce oxidative stress and neuronal death in Parkinson’s Disease. Antioxidants & Redox Signaling, 24(7), 376–391. https://doi.org/10.1089/ars.2015.6343.CrossRef

Dinkova-Kostova, A. T., Kostov, R. V., & Kazantsev, A. G. (2018). The role of Nrf2 signaling in counteracting neurodegenerative diseases. FEBS Journal. https://doi.org/10.1111/febs.14379.CrossRefPubMed

Dixon, S. J. (2017). Ferroptosis: Bug or feature? Immunological Reviews, 277(1), 150–157. https://doi.org/10.1111/imr.12533.CrossRefPubMed

Dixon, S. J., Lemberg, K. M., Lamprecht, M. R., Skouta, R., Zaitsev, E. M., Gleason, C. E.,…, Stockwell, B. R. (2012). Ferroptosis: An iron-dependent form of nonapoptotic cell death. Cell, 149(5), 1060–1072. https://doi.org/10.1016/j.cell.2012.03.042.CrossRefPubMedPubMedCentral

East, D. A., Fagiani, F., Crosby, J., Georgakopoulos, N. D., Bertrand, H., Schaap, M.,… Campanella, M. (2014). PMI: A DeltaPsim independent pharmacological regulator of mitophagy. Chemistry & Biology, 21(11), 1585–1596. https://doi.org/10.1016/j.chembiol.2014.09.019.CrossRef

Friedmann Angeli, J. P., Schneider, M., Proneth, B., Tyurina, Y. Y., Tyurin, V. A., Hammond, V. J.,… Conrad, M. (2014). Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nature Cell Biology, 16(12), 1180–1191. https://doi.org/10.1038/ncb3064.CrossRefPubMed

Gerwyn, M., & Maes, M. (2017). Mechanisms explaining muscle fatigue and muscle pain in patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): A review of recent findings. Current Rheumatology Reports, 19(1), 1. https://doi.org/10.1007/s11926-017-0628-x.CrossRefPubMed

Girotti, A. W. (1998). Lipid hydroperoxide generation, turnover, and effector action in biological systems. Journal of Lipid Research, 39(8), 1529–1542.PubMed

Grolez, G., Moreau, C., Sablonniere, B., Garcon, G., Devedjian, J. C., Meguig, S.,… Devos, D. (2015). Ceruloplasmin activity and iron chelation treatment of patients with Parkinson’s disease. BMC Neurology, 15, 74. https://doi.org/10.1186/s12883-015-0331-3.CrossRefPubMedPubMedCentral

Grondin, R., Kaytor, M. D., Ai, Y., Nelson, P. T., Thakker, D. R., Heisel, J.,… Kaemmerer, W. F. (2012). Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum. Brain, 135(Pt 4), 1197–1209. https://doi.org/10.1093/brain/awr333.CrossRefPubMedPubMedCentral

Guo, X., Disatnik, M. H., Monbureau, M., Shamloo, M., Mochly-Rosen, D., & Qi, X. (2013). Inhibition of mitochondrial fragmentation diminishes Huntington’s disease-associated neurodegeneration. The Journal of Clinical Investigation, 123(12), 5371–5388. https://doi.org/10.1172/JCI70911.CrossRefPubMedPubMedCentral

Ho, L. W., Brown, R., Maxwell, M., Wyttenbach, A., & Rubinsztein, D. C. (2001). Wild type Huntingtin reduces the cellular toxicity of mutant Huntingtin in mammalian cell models of Huntington’s disease. Journal of Medical Genetics, 38(7), 450–452.CrossRef

Ingold, I., Berndt, C., Schmitt, S., Doll, S., Poschmann, G., Buday, K.,… Conrad, M. (2018). Selenium utilization by GPX4 is required to prevent hydroperoxide-induced ferroptosis. Cell, 172(3), 409–422 e421. https://doi.org/10.1016/j.cell.2017.11.048.CrossRefPubMed

Jana, N. R., Zemskov, E. A., Wang, G., & Nukina, N. (2001). Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Human Molecular Genetics, 10(10), 1049–1059.CrossRef

Jimenez-Sanchez, M., Licitra, F., Underwood, B. R., & Rubinsztein, D. C. (2017) Huntington’s disease: Mechanisms of pathogenesis and therapeutic strategies. Cold Spring Harbor Perspectives in Medicine. https://doi.org/10.1101/cshperspect.a024240.CrossRefPubMedPubMedCentral

Johnson, W. M., Wilson-Delfosse, A. L., & Mieyal, J. J. (2012). Dysregulation of glutathione homeostasis in neurodegenerative diseases. Nutrients, 4(10), 1399–1440. https://doi.org/10.3390/nu4101399.CrossRefPubMedPubMedCentral

Joshi, Y. B., Giannopoulos, P. F., & Pratico, D. (2015). The 12/15-lipoxygenase as an emerging therapeutic target for Alzheimer’s disease. Trends in Pharmacological Sciences, 36(3), 181–186. https://doi.org/10.1016/j.tips.2015.01.005.CrossRefPubMedPubMedCentral

Kim, D. W., Hwang, I. K., Yoo, K. Y., Won, C. K., Moon, W. K., & Won, M. H. (2007). Coenzyme Q_{10} effects on manganese superoxide dismutase and glutathione peroxidase in the hairless mouse skin induced by ultraviolet B irradiation. Biofactors, 30(3), 139–147.CrossRef

Klepac, N., Relja, M., Klepac, R., Hecimovic, S., Babic, T., & Trkulja, V. (2007). Oxidative stress parameters in plasma of Huntington’s disease patients, asymptomatic Huntington’s disease gene carriers and healthy subjects: A cross-sectional study. Journal of Neurology, 254(12), 1676–1683. https://doi.org/10.1007/s00415-007-0611-y.CrossRefPubMed

Kumar, P., Kalonia, H., & Kumar, A. (2010). Nitric oxide mechanism in the protective effect of antidepressants against 3-nitropropionic acid-induced cognitive deficit, glutathione and mitochondrial alterations in animal model of Huntington’s disease. Behavioural Pharmacology, 21(3), 217–230.CrossRef

Kuo, K. H., & Mrkobrada, M. (2014). A systematic review and meta-analysis of deferiprone monotherapy and in combination with deferoxamine for reduction of iron overload in chronically transfused patients with beta-thalassemia. Hemoglobin, 38(6), 409–421. https://doi.org/10.3109/03630269.2014.965781.CrossRefPubMed

Kwan, W., Trager, U., Davalos, D., Chou, A., Bouchard, J., Andre, R.,… Muchowski, P. J. (2012). Mutant huntingtin impairs immune cell migration in Huntington disease. The Journal of Clinical Investigation, 122(12), 4737–4747. https://doi.org/10.1172/JCI64484.CrossRefPubMedPubMedCentral

Leavitt, B. R., van Raamsdonk, J. M., Shehadeh, J., Fernandes, H., Murphy, Z.,… Hayden, M. R. (2006). Wild-type huntingtin protects neurons from excitotoxicity. Journal of Neurochemistry, 96(4), 1121–1129. https://doi.org/10.1111/j.1471-4159.2005.03605.x.CrossRefPubMed

Lee, J., Kosaras, B., Del Signore, S. J., Cormier, K., McKee, A., Ratan, R. R., Kowall, N. W., & Ryu, H. (2011). Modulation of lipid peroxidation and mitochondrial function improves neuropathology in Huntington’s disease mice. Acta Neuropathologica, 121(4), 487–498. https://doi.org/10.1007/s00401-010-0788-5.CrossRefPubMed

MacDonald, M. E., Ambrose, C. M., Duyao, M. P., Myers, R. H., Lin, C., Srinidhi, L.,... MacFarlane, H. (1993). A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. The Huntington’s Disease Collaborative Research Group. Cell, 72(6), 971–983.CrossRef

Maiorino, M., Conrad, M., & Ursini, F. (2017). GPx4, lipid peroxidation, and cell death: Discoveries, rediscoveries, and open issues. Antioxidants & Redox Signaling. https://doi.org/10.1089/ars.2017.7115.CrossRef

Majumder, P., Raychaudhuri, S., Chattopadhyay, B., & Bhattacharyya, N. P. (2007). Increased caspase-2, calpain activations and decreased mitochondrial complex II activity in cells expressing exogenous huntingtin exon 1 containing CAG repeat in the pathogenic range. Cellular and Molecular Neurobiology, 27(8), 1127–1145. https://doi.org/10.1007/s10571-007-9220-7.CrossRefPubMed

Mao, Z., Choo, Y. S., & Lesort, M. (2006). Cystamine and cysteamine prevent 3-NP-induced mitochondrial depolarization of Huntington’s disease knock-in striatal cells. European Journal of Neuroscience, 23(7), 1701–1710. https://doi.org/10.1111/j.1460-9568.2006.04686.x.CrossRefPubMed

Matthews, R. T., Yang, L., Browne, S., Baik, M., & Beal, M. F. (1998). Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proceedings of the National Academy of Sciences, 95(15), 8892–8897.CrossRef

McBride, J. L., Pitzer, M. R., Boudreau, R. L., Dufour, B., Hobbs, T., Ojeda, S. R., & Davidson, B. L. (2011). Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington’s disease. Molecular Therapy, 19(12), 2152–2162. https://doi.org/10.1038/mt.2011.219.CrossRefPubMedPubMedCentral

Mealer, R. G., Murray, A. J., Shahani, N., Subramaniam, S., & Snyder, S. H. (2014). Rhes, a striatal-selective protein implicated in Huntington disease, binds beclin-1 and activates autophagy. Journal of Biological Chemistry, 289(6), 3547–3554. https://doi.org/10.1074/jbc.M113.536912.CrossRefPubMed

Merry, T. L., & Ristow, M. (2016). Nuclear factor erythroid-derived 2-like 2 (NFE2L2, Nrf2) mediates exercise-induced mitochondrial biogenesis and the anti-oxidant response in mice. The Journal of Physiology, 594(18), 5195–5207. https://doi.org/10.1113/JP271957.CrossRefPubMedPubMedCentral

Morris, G., Anderson, G., Berk, M., & Maes, M. (2013). Coenzyme Q10 depletion in medical and neuropsychiatric disorders: Potential repercussions and therapeutic implications. Molecular Neurobiology, 48(3), 883–903. https://doi.org/10.1007/s12035-013-8477-8.CrossRefPubMed

Morris, G., Berk, M., Galecki, P., Walder, K., & Maes, M. (2016). The neuro-immune pathophysiology of central and peripheral fatigue in systemic immune-inflammatory and neuro-immune diseases. Molecular Neurobiology, 53(2), 1195–1219. https://doi.org/10.1007/s12035-015-9090-9.CrossRefPubMed

Muller, M., & Leavitt, B. R. (2014). Iron dysregulation in Huntington’s disease. Journal of Neurochemistry, 130(3), 328–350. https://doi.org/10.1111/jnc.12739.CrossRefPubMed

Orr, A. L., Li, S., Wang, C. E., Li, H., Wang, J., Rong, J.,… Li, X. J. (2008). N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking. Journal of Neuroscience, 28(11), 2783–2792. https://doi.org/10.1523/JNEUROSCI.0106-08.2008.CrossRefPubMed

Paul, B. D., Sbodio, J. I., Xu, R., Vandiver, M. S., Cha, J. Y., Snowman, A. M., & Snyder, S. H. (2014). Cystathionine gamma-lyase deficiency mediates neurodegeneration in Huntington’s disease. Nature, 509(7498), 96–100. https://doi.org/10.1038/nature13136.CrossRefPubMedPubMedCentral

Prasad, K. N., & Bondy, S. C. (2016). Inhibition of early biochemical defects in prodromal Huntington’s Disease by simultaneous activation of Nrf2 and elevation of multiple micronutrients. Current Aging Science, 9(1), 61–70.CrossRef

Pringsheim, T., Wiltshire, K., Day, L., Dykeman, J., Steeves, T., & Jette, N. (2012). The incidence and prevalence of Huntington’s disease: A systematic review and meta-analysis. Movement Disorders, 27(9), 1083–1091. https://doi.org/10.1002/mds.25075.CrossRef

Proneth, B., & Conrad, M. (2018). Ferroptosis and necroinflammation, a yet poorly explored link. Cell Death & Differentiation. https://doi.org/10.1038/s41418-018-0173-9.CrossRef

Quinti, L., Casale, M., Moniot, S., Pais, T. F., Van Kanegan, M. J.,… Kazantsev, A. G. (2016). SIRT2- and NRF2-targeting thiazole-containing compound with therapeutic activity in Huntington’s Disease models. Cell Chemical Biology, 23(7), 849–861. https://doi.org/10.1016/j.chembiol.2016.05.015.CrossRefPubMed

Quinti, L., Dayalan Naidu, S., Trager, U., Chen, X., Kegel-Gleason, K., Lleres, D.,… Kazantsev, A. G. (2017). KEAP1-modifying small molecule reveals muted NRF2 signaling responses in neural stem cells from Huntington’s disease patients. Proceedings of the National Academy of Sciences, 114(23), E4676–E4685. https://doi.org/10.1073/pnas.1614943114.CrossRef

Ran, Q., Liang, H., Gu, M., Qi, W., Walter, C. A., Roberts, L. J. 2nd,… Van Remmen, H. (2004). Transgenic mice overexpressing glutathione peroxidase 4 are protected against oxidative stress-induced apoptosis. Journal of Biological Chemistry, 279(53), 55137–55146. https://doi.org/10.1074/jbc.M410387200.CrossRefPubMed

Reddy, P. H., Reddy, T. P., Manczak, M., Calkins, M. J., Shirendeb, U., & Mao, P. (2011). Dynamin-related protein 1 and mitochondrial fragmentation in neurodegenerative diseases. Brain Research Reviews, 67(1–2), 103–118. https://doi.org/10.1016/j.brainresrev.2010.11.004.CrossRefPubMed

Reddy, P. H., & Shirendeb, U. P. (2012). Mutant huntingtin, abnormal mitochondrial dynamics, defective axonal transport of mitochondria, and selective synaptic degeneration in Huntington’s disease. Biochimica et Biophysica Acta, 1822(2), 101–110. https://doi.org/10.1016/j.bbadis.2011.10.016.CrossRefPubMed

Rosas, H. D., Chen, Y. I., Doros, G., Salat, D. H., Chen, N. K., Kwong, K. K.,… Hersch, S. M. (2012). Alterations in brain transition metals in Huntington disease: An evolving and intricate story. Archives of Neurology, 69(7), 887–893. https://doi.org/10.1001/archneurol.2011.2945.CrossRefPubMedPubMedCentral

Rosenblatt, A., Liang, K. Y., Zhou, H., Abbott, M. H., Gourley, L. M., Margolis, R. L., Brandt, J., & Ross, C. A. (2006). The association of CAG repeat length with clinical progression in Huntington disease. Neurology, 66(7), 1016–1020. https://doi.org/10.1212/01.wnl.0000204230.16619.d9.CrossRefPubMed

Ross, C. A., & Tabrizi, S. J. (2011). Huntington’s disease: From molecular pathogenesis to clinical treatment. The Lancet Neurology, 10(1), 83–98. https://doi.org/10.1016/S1474-4422(10)70245-3.CrossRefPubMed

Roze, E., Saudou, F., & Caboche, J. (2008). Pathophysiology of Huntington’s disease: From huntingtin functions to potential treatments. Current Opinion in Neurology, 21(4), 497–503. https://doi.org/10.1097/WCO.0b013e328304b692.CrossRefPubMed

Sandhir, R., Sood, A., Mehrotra, A., & Kamboj, S. S. (2012). N-Acetylcysteine reverses mitochondrial dysfunctions and behavioral abnormalities in 3-nitropropionic acid-induced Huntington’s disease. Neurodegenerative Diseases, 9(3), 145–157. https://doi.org/10.1159/000334273.CrossRefPubMed

Seiler, A., Schneider, M., Forster, H., Roth, S., Wirth, E. K., Culmsee, C.,… Conrad, M. (2008). Glutathione peroxidase 4 senses and translates oxidative stress into 12/15-lipoxygenase dependent- and AIF-mediated cell death. Cell Metabolism, 8(3), 237–248. https://doi.org/10.1016/j.cmet.2008.07.005.CrossRefPubMed

Shirendeb, U. P., Calkins, M. J., Manczak, M., Anekonda, V., Dufour, B., McBride, J. L., Mao, P., & Reddy, P. H. (2012). Mutant huntingtin’s interaction with mitochondrial protein Drp1 impairs mitochondrial biogenesis and causes defective axonal transport and synaptic degeneration in Huntington’s disease. Human Molecular Genetics, 21(2), 406–420. https://doi.org/10.1093/hmg/ddr475.CrossRefPubMed

Simmons, D. A., Casale, M., Alcon, B., Pham, N., Narayan, N., & Lynch, G. (2007). Ferritin accumulation in dystrophic microglia is an early event in the development of Huntington’s disease. Glia, 55(10), 1074–1084. https://doi.org/10.1002/glia.20526.CrossRefPubMed

Skouta, R., Dixon, S. J., Wang, J., Dunn, D. E., Orman, M., Shimada, K.,… Stockwell, B. R. (2014). Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models. Journal of the American Chemical Society, 136(12), 4551–4556. https://doi.org/10.1021/ja411006a.CrossRefPubMedPubMedCentral

Sripetchwandee, J., Wongjaikam, S., Krintratun, W., Chattipakorn, N., & Chattipakorn, S. C. (2016). A combination of an iron chelator with an antioxidant effectively diminishes the dendritic loss, tau-hyperphosphorylation, amyloids-beta accumulation and brain mitochondrial dynamic disruption in rats with chronic iron-overload. Neuroscience, 332, 191–202. https://doi.org/10.1016/j.neuroscience.2016.07.003.CrossRefPubMed

Stack, C., Ho, D., Wille, E., Calingasan, N. Y., Williams, C., Liby, K., Sporn, M., Dumont, M., & Beal, M. F. (2010). Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington’s disease. Free Radical Biology and Medicine, 49(2), 147–158. https://doi.org/10.1016/j.freeradbiomed.2010.03.017.CrossRefPubMed

Subramaniam, S., Sixt, K. M., Barrow, R., & Snyder, S. H. (2009). Rhes, a striatal specific protein, mediates mutant-huntingtin cytotoxicity. Science, 324(5932), 1327–1330. https://doi.org/10.1126/science.1172871.CrossRefPubMedPubMedCentral

Turmaine, M., Raza, A., Mahal, A., Mangiarini, L., Bates, G. P., & Davies, S. W. (2000). Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington’s disease. Proceedings of the National Academy of Sciences, 97(14), 8093–8097. https://doi.org/10.1073/pnas.110078997.CrossRef

van Bergen, J. M., Hua, J., Unschuld, P. G., Lim, I. A., Jones, C. K., Margolis, R. L.,… Li, X. (2016). Quantitative susceptibility mapping suggests altered brain iron in premanifest huntington disease. AJNR American Journal of Neuroradiology, 37(5), 789–796. https://doi.org/10.3174/ajnr.A4617.CrossRefPubMed

Varela-Lopez, A., Giampieri, F., Battino, M., & Quiles, J. L. (2016). Coenzyme Q and its role in the dietary therapy against aging. Molecules, 21(3), 373. https://doi.org/10.3390/molecules21030373.CrossRefPubMedPubMedCentral

Vargiu, P., De Abajo, R., Garcia-Ranea, J. A., Valencia, A., Santisteban, P., Crespo, P., & Bernal, J. (2004). The small GTP-binding protein, Rhes, regulates signal transduction from G protein-coupled receptors. Oncogene, 23(2), 559–568. https://doi.org/10.1038/sj.onc.1207161.CrossRefPubMed

Velusamy, T., Panneerselvam, A. S., Purushottam, M., Anusuyadevi, M., Pal, P. K., Jain, S., Essa, M. M., Guillemin, G. J., & Kandasamy, M. (2017). Protective effect of antioxidants on neuronal dysfunction and plasticity in Huntington’s Disease. Oxidative Medicine and Cellular Longevity, 2017, 3279061. https://doi.org/10.1155/2017/3279061.CrossRefPubMedPubMedCentral

Vonsattel, J. P., & DiFiglia, M. (1998). Huntington disease. Journal of Neuropathology & Experimental Neurology, 57(5), 369–384.CrossRef

Wexler, N. S., Lorimer, J., Porter, J., Gomez, F., Moskowitz, C., Shackell, E.,… Landwehrmeyer, B. (2004). Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington’s disease age of onset. Proceedings of the National Academy of Sciences, 101(10), 3498–3503. https://doi.org/10.1073/pnas.0308679101.CrossRef

Wild, E., Magnusson, A., Lahiri, N., Krus, U., Orth, M., Tabrizi, S. J., & Bjorkqvist, M. (2011). Abnormal peripheral chemokine profile in Huntington’s disease. PLoS Currents, 3, RRN1231. https://doi.org/10.1371/currents.RRN1231.CrossRefPubMedPubMedCentral

Wongjaikam, S., Kumfu, S., Khamseekaew, J., Sripetchwandee, J., Srichairatanakool, S., Fucharoen, S., Chattipakorn, S. C., & Chattipakorn, N. (2016). Combined iron chelator and antioxidant exerted greater efficacy on cardioprotection than monotherapy in iron-overloaded rats. PLoS ONE, 11(7), e0159414. https://doi.org/10.1371/journal.pone.0159414.CrossRefPubMedPubMedCentral

Wu, C., Zhao, W., Yu, J., Li, S., Lin, L., & Chen, X. (2018). Induction of ferroptosis and mitochondrial dysfunction by oxidative stress in PC12 cells. Scientific Reports, 8(1), 574. https://doi.org/10.1038/s41598-017-18935-1.CrossRefPubMedPubMedCentral

Xie, Y., Hou, W., Song, X., Yu, Y., Huang, J., Sun, X., Kang, R., & Tang, D. (2016). Ferroptosis: Process and function. Cell Death and Differentiation, 23(3), 369–379. https://doi.org/10.1038/cdd.2015.158.CrossRefPubMedPubMedCentral

Yagoda, N., von Rechenberg, M., Zaganjor, E., Bauer, A. J., Yang, W. S., Fridman, D. J.,… Stockwell, B. R. (2007). RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature, 447(7146), 864–868. https://doi.org/10.1038/nature05859.CrossRefPubMedPubMedCentral

Yamamoto, M., Kensler, T. W., & Motohashi, H. (2018). The KEAP1-NRF2 system: A thiol-based sensor-effector apparatus for maintaining redox homeostasis. Physiological Reviews, 98(3), 1169–1203. https://doi.org/10.1152/physrev.00023.2017.CrossRefPubMed

Yang, W. S., SriRamaratnam, R., Welsch, M. E., Shimada, K., Skouta, R., Viswanathan, V. S.,… Stockwell, B. R. (2014). Regulation of ferroptotic cancer cell death by GPX4. Cell, 156(1–2), 317–331. https://doi.org/10.1016/j.cell.2013.12.010.CrossRefPubMedPubMedCentral

Yang, W. S., & Stockwell, B. R. (2008). Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chemistry & Biology, 15(3), 234–245. https://doi.org/10.1016/j.chembiol.2008.02.010.CrossRef

Yang, W. S., & Stockwell, B. R. (2016). Ferroptosis: Death by lipid peroxidation. Trends in Cell Biology, 26(3), 165–176. https://doi.org/10.1016/j.tcb.2015.10.014.CrossRefPubMed

Yano, H., Baranov, S. V., Baranova, O. V., Kim, J., Pan, Y., Yablonska, S.,… Friedlander, R. M. (2014). Inhibition of mitochondrial protein import by mutant huntingtin. Nature Neuroscience, 17(6), 822–831. https://doi.org/10.1038/nn.3721.CrossRefPubMedPubMedCentral

Zhang, Y., Leavitt, B. R., van Raamsdonk, J. M., Dragatsis, I., Goldowitz, D., MacDonald, M. E., Hayden, M. R., & Friedlander, R. M. (2006). Huntingtin inhibits caspase-3 activation. The EMBO Journal, 25(24), 5896–5906. https://doi.org/10.1038/sj.emboj.7601445.CrossRefPubMedPubMedCentral

Titel: The Emerging Roles of Ferroptosis in Huntington’s Disease
verfasst von: Yajing Mi
Xingchun Gao
Hao Xu
Yuanyuan Cui
Yuelin Zhang
Xingchun Gou
Publikationsdatum: 02.01.2019
Verlag: Springer US
Erschienen in: NeuroMolecular Medicine / Ausgabe 2/2019
Print ISSN: 1535-1084
Elektronische ISSN: 1559-1174
DOI: https://doi.org/10.1007/s12017-018-8518-6

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2019

C9orf72 Intermediate Alleles in Patients with Amyotrophic Lateral Sclerosis, Systemic Lupus Erythematosus, and Rheumatoid Arthritis

Hydrogen Sulfide Inhibits Formaldehyde-Induced Senescence in HT-22 Cells via Upregulation of Leptin Signaling

Optogenetic Stimulation of the Anterior Cingulate Cortex Ameliorates Autistic-Like Behaviors in Rats Induced by Neonatal Isolation, Caudate Putamen as a Site for Alteration

Pre-treatment with microRNA-181a Antagomir Prevents Loss of Parvalbumin Expression and Preserves Novel Object Recognition Following Mild Traumatic Brain Injury

MiR-34 and MiR-200: Regulator of Cell Fate Plasticity and Neural Development